When should latent tuberculosis infection be treated?

When to Treat Latent Tuberculosis Infection

Treat latent TB infection in all individuals at high risk for progression to active disease, prioritizing those with the greatest immunosuppression and recent exposure, after excluding active TB disease with chest radiography.

Strong Recommendations for LTBI Treatment

The following groups should systematically undergo testing and treatment for LTBI based on their substantially elevated risk of progression to active TB 1:

Highest Priority Groups (Strong Recommendations)

• People living with HIV/AIDS - Treatment should begin as soon as possible regardless of antiretroviral therapy status, with lifetime risk reduction lasting up to 19 years 1

• Close contacts of pulmonary TB cases (both adults and children) - Recent infection carries the highest reactivation risk, with most cases developing within 5 years 1

• Patients initiating anti-TNF therapy - These biologics substantially increase TB risk and require pre-treatment screening 1

• Patients receiving dialysis (hemodialysis or peritoneal dialysis) - Uremia-related immunosuppression increases reactivation risk 1

• Patients preparing for organ or hematological transplantation - Immunosuppression post-transplant creates high risk 1

• Patients with silicosis - Silica exposure dramatically increases TB risk 1

Conditional Recommendations (Based on Epidemiology and Resources)

These groups warrant LTBI testing and treatment depending on local TB burden and healthcare capacity 1:

• Prisoners - Congregate settings increase transmission risk
• Healthcare workers - Occupational exposure in high-risk settings
• Recent immigrants from high TB burden countries - Imported infection risk
• Homeless persons - Multiple risk factors including malnutrition and congregate living
• People who inject drugs - Associated immunosuppression and social factors

Additional High-Risk Groups Requiring Consideration

Patients on long-term immunosuppression (prednisone ≥15 mg/day for >4 weeks or other immunosuppressants) should be evaluated for LTBI treatment 2

Patients with medical comorbidities - When 2 or more risk factors are present, consider treatment: diabetes, being underweight, smoking, gastrectomy, chronic corticosteroid use 3

Essential Pre-Treatment Requirements

Before initiating LTBI treatment, you must:

1. Confirm LTBI diagnosis using tuberculin skin test (TST) or interferon-gamma release assay (IGRA) - either test is acceptable 1

2. Exclude active TB disease with chest radiography - this is mandatory to prevent acquired drug resistance and treatment failure 1

3. Assess for contraindications including current hepatotoxicity, drug interactions (especially with antiretrovirals), and pregnancy considerations 1

Key Clinical Pitfalls to Avoid

Do not treat without excluding active TB - Inadequate exclusion of active disease can lead to drug resistance and treatment failure, particularly with rifamycin-containing regimens 1

Do not delay treatment in HIV-positive patients - Even with low CD4+ counts, benefits outweigh risks; drug-drug interactions with antiretrovirals must be managed but should not prevent treatment 1

Do not assume all immunosuppressed patients need indefinite treatment - In low TB incidence settings like the United States and Japan, standard finite treatment courses are appropriate rather than prolonged therapy 3

Treatment Timing Considerations

For anti-TNF therapy patients: Ideally complete 4 weeks of LTBI treatment before starting biologics in non-urgent situations; concurrent administration is acceptable in emergencies 2

For transplant recipients: Treatment does not need completion before transplantation; resume when post-operative condition stabilizes 2

For patients on glucocorticoids: When feasible, initiate LTBI treatment one month before starting high-dose steroids 2